21 completed, 1 recruiting, 1 terminated. 12 Phase 1, 5 Phase 3, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow tedizolid phosphate: new trials by email Literature Review of tedizolid phosphate trials Research Report on tedizolid phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2023-04-20 | 2025-02-03 |
| A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014) IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate - Gram-Positive Infections | Phase 1 | Completed | Merck Sharp & Dohme LLC | 47 | 2019-02-06 | 2025-02-11 |
| A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) Tedizolid phosphate, Comparator - Acute Bacterial Skin and Skin Structure Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 100 | 2019-01-20 | 2025-07-31 |
| Tedizolid Prolonged Treatment for Prosthetic Joint Infections Tedizolid Phosphate 200 MG [Sivextro] - Prosthetic Joint Infection | Not applicable | Completed | Tourcoing Hospital | 35 | 2018-08-28 | 2021-09-08 |
| Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER) Tedizolid - Bone and Joint Infection | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 44 | 2017-02-06 | 2023-12-13 |
| Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study Tedizolid (Sivextro, BAY1192631), Linezolid - Skin Disease, Infectious | Terminated | Bayer | 108 | 2016-12-17 | 2019-10-02 | |
| A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) Tedizolid Phosphate (IV), Tedizolid Phosphate (oral suspension) - Gram-Positive Bacterial Infections | Phase 1 | Completed | Merck Sharp & Dohme LLC | 32 | 2016-05-02 | 2019-12-20 |
| Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis Tedizolid, Microdialysis Catheter Insertion - Diabetes, Wound Infection | Phase 1 | Completed | Hartford Hospital | 18 | 2016-02-23 | 2019-01-15 |
| A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004) midazolam, rosuvastatin, tedizolid phosphate - Skin Diseases, Bacterial | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2015-06-01 | 2015-08-24 |
| Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) Tedizolid Phophate, Antibiotic comparator, Aztreonam - Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2015-03-25 | 2019-08-07 |
| Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults Tedizolid phosphate - Obesity | Phase 4 | Completed | Amit.Pai | 19 | 2015-03-01 | 2017-03-15 |
| Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers DA-7218, Placebo - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 31 | 2014-05-01 | 2019-12-26 |
| Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) Tedizolid phosphate, Linezolid - Pneumonia | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 726 | 2014-01-06 | 2019-06-27 |
| Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid - Skin Diseases, Infectious | Phase 3 | Completed | Bayer | 125 | 2013-11-23 | 2018-10-04 |
| A Phase 1, Open-Label, 10 Day Safety Study TR-701 FA - Healthy Subjects | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 72 | 2012-05-17 | 2017-10-06 |
| A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response TR-701 FA with PSE, TR-701 FA Placebo with PSE - Healthy Subjects | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 18 | 2012-04-23 | 2018-08-21 |
| A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge TR-701 FA with Tyramine, Placebo-controlled withTyramine - Healthy Volunteers | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 30 | 2012-02-01 | 2016-05-03 |
| TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. TR-701 FA, Linezolid - Skin and Subcutaneous Tissue Bacterial Infections | Phase 3 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 667 | 2010-08-15 | 2018-08-29 |
| Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets - Bacterial Infections | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 90 | 2009-09-01 | 2016-05-19 |
| Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections TR-701 200 mg, TR-701 300 mg, TR-701 400 mg - Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 2 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 192 | 2008-09-17 | 2019-11-25 |
Showing 20 of 23. Sign in to see all of them.
Skin Diseases, Infectious (4) · Skin Diseases, Bacterial (3) · Wound Infection (2) · Abscess (1) · Bacteremia (1) · Bacterial Infections (1) · Cellulitis (1) · Diabetes Mellitus (1) · Erysipelas (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Obesity (1) · Osteomyelitis (1) · Pneumonia (1) · Soft Tissue Infections (1)
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (9) · Merck Sharp & Dohme LLC (4) · Bayer (2) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Amit.Pai (1) · Assistance Publique - Hôpitaux de Paris (1) · Dong-A ST Co., Ltd. (1) · Hartford Hospital (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Tourcoing Hospital (1)
United States (13) · Brazil (2) · Bulgaria (2) · France (2) · Germany (2) · Latvia (2) · Mexico (2) · Russia (2) · Ukraine (2) · Argentina (1) · Canada (1) · Colombia (1) · Czechia (1) · Georgia (1) · Guatemala (1)
Philippe G Prokocimer, MD (4) · David P Nicolau, PharmD (1) · Harmut Derendorf, PhD (1) · John Bohn, MD (1) · Kyung Sang Yu, M.D., Ph.D. (1) · Loren G Miller, MD MPH (1) · Manjunath Pai, PharmD (1) · Michael Berry, MD (1) · Nicholas Siebers, MD (1) · Philippe Prokocimer, MD (1)
PMID 23926058, PMID 23612197, PMID 27317442, PMID 14986270, PMID 15329363, PMID 16982292, PMID 18818959, PMID 20176900, PMID 20675299, PMID 22157324, PMID 22584101, PMID 22687509, PMID 23403680, PMID 23988422, PMID 24450727, PMID 24989138, PMID 25135090, PMID 25139552, PMID 25246392, PMID 25331703, PMID 25421472, PMID 25650692, PMID 26232669, PMID 26457865, PMID 26906190, PMID 27185808, PMID 27530088, PMID 27941424, PMID 28003218, PMID 28264845, PMID 28865799, PMID 29899212, PMID 33395210, PMID 33710976, PMID 33720350, PMID 35718656, PMID 40233296
2017 (2), 2014 (1), 2015 (1), 2016 (1)